Greenwich Lifesciences Inc
General ticker "GLSI" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $177.8M
Greenwich Lifesciences Inc follows the US Stock Market performance with the rate: 35.0%.
Estimated limits based on current volatility of 2.8%: low 12.17$, high 12.86$
Factors to consider:
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [6.16$, 13.96$]
- 2024-12-30 to 2025-12-30 estimated range: [5.25$, 12.24$]
Financial Metrics affecting the GLSI estimates:
- Negative: Non-GAAP EPS, $ of -0.71 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: Operating cash flow per share per price, % of -4.30 <= 2.35
- Negative: negative Net income
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term GLSI quotes
Long-term GLSI plot with estimates
Financial data
YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|
Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
Operating Expenses | $4.60MM | $8.04MM | $9.33MM |
Operating Income | $-4.60MM | $-8.04MM | $-9.33MM |
Non-Operating Income | $0.03MM | $0.22MM | $0.44MM |
R&D Expense | $3.56MM | $6.48MM | $7.70MM |
Income(Loss) | $-4.57MM | $-7.83MM | $-8.89MM |
Profit(Loss) | $-4.57MM | $-7.83MM | $-8.89MM |
Stockholders Equity | $26.83MM | $13.21MM | $6.70MM |
Assets | $27.22MM | $13.48MM | $6.99MM |
Operating Cash Flow | $-4.29MM | $-6.20MM | $-6.48MM |
Financing Cash Flow | $2.84MM | $-7.54MM | $0.00MM |
Earnings Per Share* | $-0.35 | $-0.59 | $-0.69 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.